Extended-release niacin/lovastatin: the first combination product for dyslipidemia

References

• Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106, 3143–3421 (2002).
   PubMed Web of Science ®Google Scholar
• Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344, 1383–1389 (1994).
   PubMed Web of Science ®Google Scholar
• Shepherd J, Cobbe SM, Ford I et al. forthe West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J. Med. 333, 1301–1307 (1995).
   PubMed Web of Science ®Google Scholar
• Sacks FM, Pfeffer MA, Moye LA et al. for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J. Med. 335, 1001–1009 (1996).
   PubMed Web of Science ®Google Scholar
• Downs JR, Clearfield M, Weis S et al. for the Air Force/Texas Coronary Atherosclerosis Prevention Study. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. J. Am. Med. Assoc. 279, 1615–1622 (1998).
   PubMed Web of Science ®Google Scholar
• The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J. Med. 339, 1349–1357 (1998).
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360, 7–22 (2002).
   PubMed Web of Science ®Google Scholar
• Sever PS, Dahliff B, Poulter NR et al for the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361, 1149–1158 (2003).
   PubMed Web of Science ®Google Scholar
• Cannon CP, Braunwald E, McCabe CH et al for the Pravastatin or Atorvastatin Evaluation and Infection Therapy — Thrombolysis In Myocardial Infarction (TIMI) 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350, 1495–1504 (2004).
   PubMed Web of Science ®Google Scholar
• Shepherd J, Blauw GJ, Murphy MB et al on behalf of the PROSPER study group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 360, 1623–1630 (2002).
   PubMed Web of Science ®Google Scholar
• Bays H. Existing and investigational combination drug therapy for high-density lipoprotein cholesterol. Am. J. Cardiol 90, 30–43 (2002).
   Web of Science ®Google Scholar
• Colquhoun D, Keech A, Hunt D, Marschner I et al for the LIPID Study Investigators. Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study. Eur Heart J. 25, 771–777 (2004).
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Dyslipidemia management in adults with diabetes. Diabetes Care 27\(Suppl. 1), S68—S71 (2004).
   Google Scholar
• Genest J, Frohlich J, Fodor G, McPherson R, the Working Group on Hypercholesterolemia and Other Dyslipidemias. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. Can. Med Assoc. J. 169, 921–924 (2003).
   PubMed Web of Science ®Google Scholar
• Bays HE, McGovern ME. Once-daily niacin extended release/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution than atorvastatin and simvastatin. Ant Cardiol 6, 179–188 (2003).
   Google Scholar
• ••Reviews practical considerations oflipoprotein particle size in the clinical management of patients, as supported by clinical trial analysis.
   Google Scholar
• Sacks FM, for the Expert Group on HDL Cholesterol. The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. Am. J. Cardid 90, 139–143 (2002).
   PubMed Web of Science ®Google Scholar
• •Many feel that high-density lipoprotein cholesterol (HDL-C) treatment goals may reduce coronary heart disease (CHD) risk
   Google Scholar
• Gotto AM Jr, Brinton EA. Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report and update. J Am. Coll Cardiol 43, 717–724 (2004).
   PubMed Web of Science ®Google Scholar
• •Demonstrates that low HDL-C is an important CHD risk factor.
   Google Scholar
• Advicor® (niacin extended release and lovastatin tablets) prescribing information. In: Physicians' Desk Reference 58th Edition. Thomson PDR NJ, USA, 1797–1801 (2004).
   Google Scholar
• Niaspan® (niacin extended-release tablets) prescribing information. In: Physicians' Desk Refitcnce® 58th Edition. Thomson PDR (Eds). Medical Economics NJ, USA 1797–1801 (2004).
   Google Scholar
• Piepho RW. The pharmacokinetics and pharmacodynamics of agents proven to raise high-density lipoprotein cholesterol. Am. J. Cardiol 86(Suppl. 12A), L35—L40 (2000).
   PubMedGoogle Scholar
• Gupta EK, Ito MK. Lovastatin and extended- release niacin combination product: the first drug combination for the management of hyperlipidemia. Heart Dis. 4, 124–137 (2002).
   PubMedGoogle Scholar
• Kamanna VS, Kashyap ML. Mechanism of action of niacin on lipoprotein metabolism. Curr Atheroscler. Rep. 2, 36–46 (2000).
   PubMedGoogle Scholar
• Wang W, Basinger A, Neese RA et al Effect of nicotinic acid administration on hepatic very low density lipoprotein-triglyceride production. Am. J. Physid Endocrind 280, E540—E547 (2001).
   PubMed Web of Science ®Google Scholar
• Ganji SH, Kamanna VS, Kashyap ML. Niacin and cholesterol: role in cardiovascular disease (review). J. Nutt: Biochem. 14, 298–305 (2003).
   PubMed Web of Science ®Google Scholar
• Morgan JM, Capuzzi DM, Guyton JR et al Treatment effect of Niaspan, a controlled-release niacin, in patients with hypercholesterolemia: a placebo-controlled trial. J. Cardiovasc. Pharmacol Ther. 1, 195–202 (1996).
   Google Scholar
• Goldberg A, Alagona P Jr, Capuzzi DM et al Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am. J. Cardiol 85,1100–1105 (2000).
   Google Scholar
• Morgan JM, Capuzzi DM, Baksh RI et al Effects of extended-release niacin on lipoprotein subclass distribution. Am. J. Cardiol 91, 1432–1436 (2003).
   PubMed Web of Science ®Google Scholar
• •Niacin improves lipoprotein particle size and subclass distribution.
   Google Scholar
• Rosenson RS. Antiatherothrombotic effects of nicotinic acid. Atherosclerosis 171, 87–96 (2003).
   PubMed Web of Science ®Google Scholar
• Grundy SM, Vega GL, McGovern ME et al for the Diabetes Multicenter Research Group. Efficacy, safety and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the Assessment of Diabetes Control and Evaluation of the Efficacy of Niaspan Trial. Arch. Intern. Med 162, 1568–1576 (2002).
   PubMed Web of Science ®Google Scholar
• •Demonstrates that niacin is a safe and effective treatment of dyslipidemia in diabetes mellitus.
   Google Scholar
• Kuvin JT, REmet ME, Patel AR, Pandian NG, Mendelsohn ME, Karas RH. A novel mechanism for the beneficial vascular effects of high-density lipoprotein cholesterol: enhanced vasorelaxation and increased endothelial nitric oxide synthase expression. Am. Heart J 144, 165–172 (2002).
   PubMed Web of Science ®Google Scholar
• Capuzzi DM, Guyton JR, Morgan JM et al Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Am. J. Cardiol 82, 74U-81U (1998).
   Google Scholar
• Knopp RH, Alagona P, Davidson M et al Equivalent efficacy of a time-release form of niacin (Niaspan) given once a night versus plain niacin in the management of hyperlipidemia. Metabolism 47, 1097–1104 (1998).
   PubMed Web of Science ®Google Scholar
• Moon YS, Kashyap ML. Niacin extended- release/lovastatin: combination therapy for lipid disorders. Expert Opin. Pharmacother. 3(12), 1763–1771 (2002).
   PubMedGoogle Scholar
• ••Extended-release niacin in a fixed-dosecombination with lovastatin is a safe and effective treatment for complex dyslipidemias.
   Google Scholar
• Bradford RH, Shear CL, Chremos AN et al Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch. Intern. Med. 151, 43–49 (1991).
   PubMed Web of Science ®Google Scholar
• Rosenson RS, Tangney CC. Anti-atherothrombotic properties of statins: implications for cardiovascular event reduction. J. Am. Med. Assoc. 279, 1643–1650 (1998).
   PubMed Web of Science ®Google Scholar
• Bays H, Stein EA. Pharmacotherapy for dyslipidaemia — current therapies and future agents. Expert Opin. Pharmacother. 4(11), 1901–1938 (2003).
   PubMed Web of Science ®Google Scholar
• •• Extensive and comprehensive review of lipid-altering drug treatments.
   Google Scholar
• Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Arch. Intern. Med. 148, 36–69 (1988).
   PubMedGoogle Scholar
• Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 269, 3015–3023 (1993).
   PubMed Web of Science ®Google Scholar
• Mosca L, Appel LJ, Benjamin EJ et al. Evidence-based guidelines for cardiovascular disease prevention in women. Circulation 109, 672–693 (2004).
   PubMed Web of Science ®Google Scholar
• McKenney J. New perspectives on the use of niacin in the treatment of lipid disorders. Arch. Intern. Med. 164, 697–705 (2004).
   PubMed Web of Science ®Google Scholar
• •• Niacin continues to be an important treatment option for dyslipidemia.
   Google Scholar
• The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 231, 360–381 (1975).
   PubMed Web of Science ®Google Scholar
• •Study results published in the 1970s still have substantial relevance today.
   Google Scholar
• Canner PL, Berge KG, Wenger NK et al., for the Coronary Drug Project Research Group. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J. Am. Coll. Cardiol 8, 1245–1255 (1986).
   PubMed Web of Science ®Google Scholar
• ••Niacin is one of the few lipid-alteringdrug treatments shown to reduce overall mortality.
   Google Scholar
• Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol—niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 257, 3233–3240 (1987).
   PubMed Web of Science ®Google Scholar
• Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med. Scand. 223,405–418 (1988).
   PubMed Web of Science ®Google Scholar
• Cashin-Hemphill L, Mack WJ, Pogoda JM, Sanmarco ME, Azen SP, Blankenhorn DH. Beneficial effects of colestipol—niacin on coronary atherosclerosis: a 4-year follow-up. J. Am. Med. Assoc. 264,3013–3017 (1990).
   PubMed Web of Science ®Google Scholar
• Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. J. Am. Med. Assoc. 264,3007–3012 (1990).
   PubMed Web of Science ®Google Scholar
• Blankenhorn DH, Selzer RH, Crawford DW et al. Beneficial effects of colestipol—niacin therapy on the common carotid artery. 2- and 4-year reduction of intima-media thickness measured by ultrasound. Circulation 88,20–28 (1993).
   PubMed Web of Science ®Google Scholar
• Blankenhorn DH, Azen SP, Crawford DW et al. Effects of colestipol-niacin therapy on human femoral atherosclerosis. Circulation 83,438–447 (1991).
   PubMed Web of Science ®Google Scholar
• Sacks FM, Pasternak RC, Gibson CM, Rosner B, Stone PH, for the Harvard Atherosclerosis Reversibility Project (HARP) Group. Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Lancet 344,1182–1186 (1994).
   PubMed Web of Science ®Google Scholar
• Nissen SE. Application of intravascular ultrasound to characterize coronary artery disease and assess the progression or regression of atherosclerosis. Am. J. CardioL 89, B24—B31 (2002).
   Web of Science ®Google Scholar
• Waters D. Lessons from coronary atherosclerosis 'regression' trials. Cardiol. Clin. 14,31–50 (1996).
   PubMedGoogle Scholar
• Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl. J. Med. 336,153–162 (1997).
   PubMed Web of Science ®Google Scholar
• Blankenhorn DH, Azen SP, Kramsch DM et al. and The MARS Research Group. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). Ann. Intern. Med. 119, 969–976 (1993).
   PubMed Web of Science ®Google Scholar
• Waters D, Higginson L, Gladstone P et al Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: the Canadian Coronary Atherosclerosis Intervention Trial. Circulation 89,959–968 (1994).
   PubMed Web of Science ®Google Scholar
• Furberg CD, Adams HP Jr, Applegate WB et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation 90,1679–1687 (1994).
   PubMed Web of Science ®Google Scholar
• Brown G, Albers JJ, Fisher LD et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N EngL J. Med. 323,1289–1298 (1990).
   PubMed Web of Science ®Google Scholar
• Brown BG, Brockenbrough A, Zhao XQ et al. Very intensive lipid therapy with lovastatin, niacin and colestipol for prevention of death and myocardial infarction: a 10-year familial atherosclerosis treatment study (FATS) follow-up. Circulation 98(Suppl. I), 1635 (1998) (Abstract 3341).
   Google Scholar
• •Combination of niacin and statin treatment has favorable effects upon CHD outcomes.
   Google Scholar
• Brown BG, Zhao XQ, Chait A et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N EngL J. Med. 345,1583–1592 (2001).
   PubMed Web of Science ®Google Scholar
• ••The combination of niacin and statintreatment may reduce CHD risk by as much as 60 to 90%.
   Google Scholar
• Hunninghake DB, McGovern ME, Koren M et al. A dose-ranging study of a new, once-daily dual-component drug product containing niacin extended-release and lovastatin. Clin. CardioL 26,112–118 (2003).
   PubMed Web of Science ®Google Scholar
• Kashyap ML, McGovern ME, Berra K et al Long-term safety and efficacy of a once-daily niacin/lovastatin formulation in patients with dyslipidemia. Am. J. CardioL 89,672–678 (2002).
   PubMed Web of Science ®Google Scholar
• •Extended-release niacin/lovastatin combination product has long-term safety and efficacy
   Google Scholar
• Bays HE, Dujovne CA, McGovern ME et al. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-modulating Agents Trial Evaluation [ADVOCATE]). Am. J. CardioL 91, 667–672 (2003).
   PubMed Web of Science ®Google Scholar
• •• Extended-release niacin/lovastatin combination product has more favorable effects upon multiple lipid parameters than statin alone.
   Google Scholar
• Van JT, Pan J, Wasty T, Chan E, Wu X, Charles MA. Comparison of extended-release niacin and atorvastatin monotherapies and combination treatment of the atherogenic lipid profile in diabetes mellitus. Am. J. CardioL 89, 1306–1308 (2002).
   PubMed Web of Science ®Google Scholar
• Zhao X-Q, Morse JS, Dowdy AA et al. Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study). Am. J. CardioL 93, 307–312 (2004).
   PubMed Web of Science ®Google Scholar
• ••Combination of niacin and statin issafe, and if properly administered, tolerable in a large majority of patients.
   Google Scholar
• Bays HE. Trial finds that simvastatin plus niacin is safe in people with coronary artery disease and low HDL cholesterol. Evidence Based Cardiovasc. Med. 8(2) 171–172 (2004).
   PubMedGoogle Scholar
• Morrow JD, Awad JA, Oates JA, Roberts U. Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans. J. Invest. DermatoL 98,812–815 (1992).
   PubMed Web of Science ®Google Scholar
• Capuzzi DM, Morgan JM, Brusco OAJ, Intenzo CM. Niacin dosing: relationship to benefits and adverse effects. Curr. Atheroscler. Rep. 2,64–71 (2000).
   PubMedGoogle Scholar
• McKenney JM. Niacin for dyslipidemia: considerations in product selection. Am. J. Health Syst. Pharm. 60,995–1005 (2003).
   PubMed Web of Science ®Google Scholar
• Bays HE. Efficacy and safety of niacin extended-release/lovastatin compared with atorvastatin and simvastatin. CardioL Rev. 20,34–38 (2003).
   Google Scholar
• Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J. Am. Coll. CardioL 40,567–572 (2002).
   PubMed Web of Science ®Google Scholar
• Tolman KG. The liver and lovastatin. Am. J. CardioL 89,1374–1380 (2002).
   PubMed Web of Science ®Google Scholar
• Bays H. Ezetimibe. Expert Opin. Investig. Drugs. 11(11), 1587–1604 (2002).
   PubMed Web of Science ®Google Scholar
• Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann. Pharmacother. 36, 288–295 (2002).
   PubMed Web of Science ®Google Scholar
• Garg A, Grundy SM. Nicotinic acid as therapy for dyslipidemia in noninsulin-dependent diabetes mellitus. J. Am. Med. Assoc. 264,723–726 (1990).
   PubMed Web of Science ®Google Scholar
• •Niacin is an effective treatment for diabetes dyslipidemia.
   Google Scholar
• Elam MB, Hunninghake DB, Davis KB et al. for the ADMIT Investigators. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease. The ADMIT study: a randomized trial. J. Am. Med. Assoc. 284,1263–1270 (2000).
   PubMed Web of Science ®Google Scholar
• •Niacin is a safe treatment for a large majority of patients with diabetes mellitus.
   Google Scholar
• Canner PL, Furberg CD, McGovern ME. Niacin decreases myocardial infarction and total mortality in patients with impaired fasting glucose or glucose intolerance: results from the Coronary Drug Project. Circulation 106 (Suppl. II), 11–636 (2002).
   PubMedGoogle Scholar
• •Patients who may benefit the most from niacin treatment are those with higher fasting glucose levels.
   Google Scholar
• Canner PL, Furberg CD, Terrin ML, McGovern ME. Niacin decreases myocardial infarction and total mortality in patients with metabolic syndrome: results from the Coronary Drug Project. J. Am. Coll. Cardid. 41(Suppl. A), A291 (2003).
   Google Scholar
• •Niacin reduces CHD risk.
   Google Scholar
• Morse JS, Brown BG, Zhao X-Q et al Niacin plus simvastatin protect against atherosclerosis progression and clinical events in CAD patients with low HDL-C and diabetes mellitus or impaired fasting glucose. J Am. ColL Cardid 37(Suppl. A), A262 (2001).
   Google Scholar
• •Niacin and statin is an effective combination, not only to improve lipid parameters, but also in reducing CHD events in patients with diabetes mellitus or impaired fasting glucose.
   Google Scholar
• Nissen SE, Tuzcu EM, Schoenhagen P et al Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial./ Am. Med. Assoc. 291, 1071–1080 (2004).
   PubMed Web of Science ®Google Scholar
• Bays HE, Ose L, Fraser N et al Ezetimibe/simvastatin therapy is more effective than simvastatin alone at reducing remnant-like particle cholesterol./ Am Coll Cardid 43(Suppl. A), 481 (2004).
   Google Scholar
• Brousseau ME, Schaefer EJ, Wolfe ML et al Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N EngL J Med. 350, 1505–1515 (2004).
   PubMed Web of Science ®Google Scholar
• Wise A, Foord SM, Fraser NJ et al. Molecular identification of high and low affinity receptors for nicotinic acid. J. Biol. Chem. 278, 9869–9874 (2003).
   PubMed Web of Science ®Google Scholar
• Tunaru S, Kero J, Schaub A et al. PUMA-G and HM74 are receptors for nicotinic acid and mediate its antilipolytic effect. Nature Med. 9, 352–355 (2003).
   PubMed Web of Science ®Google Scholar
• Davidson MH. Combination therapy for dyslipidemia: safety and regulatory considerations. Am. J. Cardid 90(Suppl.), K50—K60 (2002).
   PubMedGoogle Scholar
• Xydakis AM, Ballantyne CM. Combination therapy for combined dyslipidemia. Am. J. Cardiol. 90(Suppl. 2), 21–29 (2002).
   Google Scholar